Preparation of extracellular domain 3 of human VEGF receptor‐2 and the monitoring of its real‐time binding to VEGF by biosensors

Vascular endothelial growth factor receptor‐2 (VEGFR‐2) plays an important role in stimulating the proliferation of endothelial cells and improving the permeability of blood vessels, which is involved in tumor angiogenesis, a process that is essential for tumor growth and metastasis. In this study, we describe a method for high yield of recombinant extracellular domain 3 (KDR3) of human VEGFR‐2 in an Escherichia coli system with further purification by cation exchange chromatography and immobilized metal affinity chromatography (IMAC). The biological activity of recombinant KDR3 was performed by sequestering VEGF in HUVEC proliferation assay. The real‐time binding of human VEGF to immobilized KDR3 was monitored by a label‐free biosensor, Optical waveguide lightmode spectroscopy (OWLS). Under the given experimental conditions, the association rate constant ka was 4.2 × 103 M−1 s−1 and the dissociation rate kd was 5.1 × 10−3 s−1. The dissociation constant KD was then calculated to be 1.2 × 10−6 M. The obtained values will serve as baseline parameters for the design of improved versions of recombinant soluble VEGF receptors and the evaluation of developed anti‐KDR antibodies. In addition, such a scenario established by the use of OWLS will potentiate the kinetic study of ligand/receptor and antigen/antibody. The receptor discussed here, which block VEGF binding to cell membrane KDR, have potential clinical application in the treatment of cancer and other diseases where pathological angiogenesis is involved. © 2009 American Institute of Chemical Engineers Biotechnol. Prog., 2009

[1]  Zhen-ping Zhu,et al.  Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. , 2006, Biochemical and biophysical research communications.

[2]  B. Kou,et al.  In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. , 2004, Experimental and molecular pathology.

[3]  P. Bohlen,et al.  Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy , 2002, International journal of cancer.

[4]  M. Váradi,et al.  Modification of the surface of integrated optical wave-guide sensors for immunosensor applications , 2001, Fresenius' journal of analytical chemistry.

[5]  P. R. V. Tassel,et al.  Kinetic Regimes of Protein Adsorption , 2001 .

[6]  P. Gerwins,et al.  Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. , 2000, Critical reviews in oncology/hematology.

[7]  P. Bohlen,et al.  Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies* , 2000, The Journal of Biological Chemistry.

[8]  P E Thorpe,et al.  Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. , 1998, Biochemical and biophysical research communications.

[9]  Ramsden,et al.  A Particle-Level Model of Irreversible Protein Adsorption with a Postadsorption Transition. , 1998, Journal of colloid and interface science.

[10]  K. Alfthan,et al.  Surface plasmon resonance biosensors as a tool in antibody engineering. , 1998, Biosensors & bioelectronics.

[11]  K.,et al.  Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Hicklin,et al.  Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.

[13]  B. Li,et al.  Requirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor* , 1998, The Journal of Biological Chemistry.

[14]  J. Ramsden,et al.  Kinetics of the interaction between DNA and the type IC restriction enzyme EcoR124II. , 1996, Biochemistry.

[15]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[16]  R. Karlsson,et al.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.

[17]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[18]  Liu Yu Pichia Expression of Recombined Human VEGF_(165) and Activity Determination , 2004 .

[19]  M. Clauss Molecular Biology of the VEGF and the VEGF Receptor Family , 2000, Seminars in thrombosis and hemostasis.

[20]  M. Dewhirst,et al.  Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.